CD47 is an adverse prognostic factor and a therapeutic target in gastric cancer

Cancer Medicine

Volumn 4, Issue 9, 2015, Pages 1322-1333

  Yoshida, Kazumichi ^a   Tsujimoto, Hironori ^a   Matsumura, Kouji ^a   Kinoshita, Manabu ^a   Takahata, Risa ^a   Matsumoto, Yusuke ^a   Hiraki, Shuichi ^a   Ono, Satoshi ^a   Seki, Shuhji ^a   Yamamoto, Junji ^a   Hase, Kazuo ^a  

^a NATIONAL DEFENSE MEDICAL COLLEGE   (Japan)

Author keywords

CD44; CD47; Gastric cancer; Phagocytosis

Indexed keywords

CD47 ANTIGEN; HERMES ANTIGEN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CD47; UNCLASSIFIED DRUG; TUMOR MARKER;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; CARCINOGENICITY; CELL PROLIFERATION; CELL SELECTION; COLONY FORMATION; CONTROLLED STUDY; FEMALE; FLUORESCENCE ACTIVATED CELL SORTING; GASTRIC CANCER CELL LINE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MACROPHAGE; MAJOR CLINICAL STUDY; MALE; MKN45 CELL; MKN74 CELL; MOUSE; NONHUMAN; PHAGOCYTOSIS; PRIORITY JOURNAL; SPHEROID CELL; STOMACH CANCER; SURVIVAL TIME; TUMOR ENGRAFTMENT; AGED; ANIMAL; APOPTOSIS; CANCER STAGING; CELL TRANSFORMATION; DISEASE MODEL; DRUG EFFECTS; DRUG SCREENING; GENE EXPRESSION; GENETICS; IMMUNOPHENOTYPING; METABOLISM; METASTASIS; MIDDLE AGED; MOLECULARLY TARGETED THERAPY; MORTALITY; PROGNOSIS; STOMACH NEOPLASMS; TUMOR CELL LINE;

ADULT; AGED; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD44; ANTIGENS, CD47; APOPTOSIS; BIOMARKERS, TUMOR; CELL LINE, TUMOR; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; DISEASE MODELS, ANIMAL; FEMALE; GENE EXPRESSION; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; MACROPHAGES; MALE; MICE; MIDDLE AGED; MOLECULAR TARGETED THERAPY; NEOPLASM METASTASIS; NEOPLASM STAGING; PHAGOCYTOSIS; PROGNOSIS; STOMACH NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 85006219342     PISSN: None     EISSN: 20457634     Source Type: Journal    
DOI: 10.1002/cam4.478     Document Type: Article

References (41)

1. Tsujimoto, H., S. Ono, T. Ichikura, Y. Matsumoto, J. Yamamoto, and K. Hase. 2011. Roles of inflammatory cytokines in the progression of gastric cancer: friends or foes? Gastric Cancer 13:212-221.
2. Parkin, D. M. 2004. International variation. Oncogene 23:6329-6340.
3. Reya, T., S. J. Morrison, M. F. Clarke, and I. L. Weissman. 2001. Stem cells, cancer, and cancer stem cells. Nature 414:105-111.
4. Clarke, M. F., and M. Fuller. 2006. Stem cells and cancer: two faces of eve. Cell 124:1111-1115.
5. Wakamatsu, Y., N. Sakamoto, H. Z. Oo, Y. Naito, N. Uraoka, K. Anami, et al. 2012. Expression of cancer stem cell markers ALDH1, CD44 and CD133 in primary tumor and lymph node metastasis of gastric cancer. Pathol. Int. 62:112-119.
6. Majeti, R., M. P. Chao, A. A. Alizadeh, W. W. Pang, S. Jaiswal, K. D. Gibbs Jr., et al. 2009. CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells. Cell 138:286-299.
7. Chan, K. S., J. P. Volkmer, and I. Weissman. 2010. Cancer stem cells in bladder cancer: a revisited and evolving concept. Curr. Opin. Urol. 20:393-397.
8. Takaishi, S., T. Okumura, S. Tu, S. W. Wang Sophie, W. Shibata, R. Vigneshwaran, et al. 2009. Identification of gastric cancer stem cells using the cell surface marker CD44. Stem Cells 27:1006-1020.
9. Jaiswal, S., C. H. Jamieson, W. W. Pang, C. Y. Park, M. P. Chao, R. Majeti, et al. 2009. CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis. Cell 138:271-285.
10. Wenqi, D., W. Li, C. Shanshan, C. Bei, Z. Yafei, B. Feihu, et al. 2009. EpCAM is overexpressed in gastric cancer and its downregulation suppresses proliferation of gastric cancer. J. Cancer Res. Clin. Oncol. 135:1277-1285.
11. Takaishi, S., T. Okumura, and T. C. Wang. 2008. Gastric cancer stem cells. J. Clin. Oncol. 26:2876-2882.
12. Muller, W., A. Schneiders, K. H. Heider, S. Meier, G. Hommel, and H. E. Gabbert. 1997. Expression and prognostic value of the CD44 splicing variants v5 and v6 in gastric cancer. J. Pathol. 183:222-227.
13. Yamaguchi, A., T. Goi, J. Yu, Y. Hirono, M. Ishida, A. Iida, et al. 2002. Expression of CD44v6 in advanced gastric cancer and its relationship to hematogenous metastasis and long-term prognosis. J. Surg. Oncol. 79:230-235.
14. Ishimoto, T., O. Nagano, T. Yae, M. Tamada, T. Motohara, H. Oshima, et al. 2011. CD44 variant regulates redox status in cancer cells by stabilizing the xCT subunit of system xc(-) and thereby promotes tumor growth. Cancer Cell 19:387-400.
15. Matozaki, T., Y. Murata, H. Okazawa, and H. Ohnishi. 2009. Functions and molecular mechanisms of the CD47-SIRPalpha signalling pathway. Trends Cell Biol. 19:72-80.
16. Ide, K., H. Wang, H. Tahara, J. Liu, X. Wang, T. Asahara, et al. 2007. Role for CD47-SIRPalpha signaling in xenograft rejection by macrophages. Proc. Natl. Acad. Sci. USA 104:5062-5066.
17. Brown, E. J., and W. A. Frazier. 2011. Integrin-associated protein (CD47) and its ligands. Trends Cell Biol. 11:130-135.
18. Chan, K. S., I. Espinosa, M. Chao, D. Wong, L. Ailles, M. Diehn, et al. 2009. Identification, molecular characterization, clinical prognosis, and therapeutic targeting of human bladder tumor-initiating cells. Proc. Natl. Acad. Sci. USA 106:14016-14021.
19. Sick, E., A. Boukhari, T. Deramaudt, P. Ronde, B. Bucher, P. Andre, et al. 2011. Activation of CD47 receptors causes proliferation of human astrocytoma but not normal astrocytes via an Akt-dependent pathway. Glia 59:308-319.
20. Willingham, S. B., J. P. Volkmer, A. J. Gentles, D. Sahoo, P. Dalerba, S. S. Mitra, et al. 2012. The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors. Proc. Natl. Acad. Sci. USA 109:6662-6667.
21. Edris, B., K. Weiskopf, A. K. Volkmer, J. P. Volkmer, S. B. Willingham, H. Contreras-Trujillo, et al. 2012. Antibody therapy targeting the CD47 protein is effective in a model of aggressive metastatic leiomyosarcoma. Proc. Natl. Acad. Sci. USA 109:6656-6661.
22. Mateo, V., L. Lagneaux, D. Bron, G. Biron, M. Armant, G. Delespesse, et al. 1999. CD47 ligation induces caspase-independent cell death in chronic lymphocytic leukemia. Nat. Med. 5:1277-1284.
23. Kaur, S., and D. D. Roberts. 2011. CD47 applies the brakes to angiogenesis via vascular endothelial growth factor receptor-2. Cell Cycle 10:10-12.
24. Zhao, X. W., E. M. van Beek, K. Schornagel, X. W. Zhao, E. M. van Beek, K. Schornagel, et al. 2011. CD47-signal regulatory protein-α (SIRPα) interactions form a barrier for antibody-mediated tumor cell destruction. Proc. Natl. Acad. Sci. USA 108:18342-18347.
25. Chao, M. P., A. A. Alizadeh, C. Tang, M. Jan, R. Weissman-Tsukamoto, F. Zhao, et al. 2011. Therapeutic antibody targeting of CD47 eliminates human acute lymphoblastic leukemia. Cancer Res. 71:1374-1384.
26. Kaczorowski, D. J., and T. R. Billiar. 2007. Targeting CD47: NO limit on therapeutic potential. Circ. Res. 100:602-603.
27. Sobin, L. H., M. K. Gospodarowicz, and C. Wittekind ; International Union against Cancer. 2010. TNM classification of malignant tumours. Wiley-Blackwell, Chichester, West Sussex, U.K.; Hoboken, NJ.
28. Way, K. J., H. Dinh, M. R. Keene, K. J. Way, H. Dinh, M. R. Keene, et al. 2009. The generation and properties of human macrophage populations from hemopoietic stem cells. J. Leukoc. Biol. 85:766-778.
29. Brugger, W., M. Kreutz, and R. Andreesen. 1991. Macrophage colony-stimulating factor is required for human monocyte survival and acts as a cofactor for their terminal differentiation to macrophages in vitro. J. Leukoc. Biol. 49:483-488.
30. Becker, S., M. K. Warren, and S. Haskill. 1987. Colony-stimulating factor-induced monocyte survival and differentiation into macrophages in serum-free cultures. J. Immunol. 139:3703-3709.
31. Ricci-Vitiani, L., D. G. Lombardi, E. Pilozzi, M. Biffoni, M. Todaro, C. Peschle, et al. 2007. Identification and expansion of human colon-cancer-initiating cells. Nature 445:111-115.
32. Barclay, A. N., and M. H. Brown. 2006. The SIRP family of receptors and immune regulation. Nat. Rev. Immunol. 6:457-464.
33. Blazar, B. R., F. P. Lindberg, E. Ingulli, A. Panoskaltsis-Mortari, P. A. Oldenborg, K. Iizuka, et al. 2001. CD47 (integrin-associated protein) engagement of dendritic cell and macrophage counterreceptors is required to prevent the clearance of donor lymphohematopoietic cells. J. Exp. Med. 194:541-549.
34. Okazawa, H., S. Motegi, N. Ohyama, H. Ohnishi, T. Tomizawa, Y. Kaneko, et al. 2005. Negative regulation of phagocytosis in macrophages by the CD47-SHPS-1 system. J. Immunol. 174:2004-2011.
35. Zhao, X. W., H. L. Matlung, T. W. Kuijpers, and T. K. van den Berg. 2012. On the mechanism of CD47 targeting in cancer. Proc. Natl. Acad. Sci. USA 109:2844-2845.
36. Andersen, J. T., M. B. Daba, G. Berntzen, T. E. Michaelsen, and I. Sandlie. 2010. Cross-species binding analyses of mouse and human neonatal Fc receptor show dramatic differences in immunoglobulin G and albumin binding. J. Biol. Chem. 285:4826-4836.
37. Zhou, J., J. E. Johnson, V. Ghetie, R. J. Ober, and E. S. Ward. 2003. Generation of mutated variants of the human form of the MHC class I-related receptor, FcRn, with increased affinity for mouse immunoglobulin G. J. Mol. Biol. 332:901-913.
38. Uno, S., Y. Kinoshita, Y. Azuma, T. Tsunenari, Y. Yoshimura, S. Iida, et al. 2007. Antitumor activity of a monoclonal antibody against CD47 in xenograft models of human leukemia. Oncol. Rep. 17:1189-1194.
39. Washington, K., M. R. Gottfried, and M. J. Telen. 1994. Expression of the cell adhesion molecule CD44 in gastric adenocarcinomas. Hum. Pathol. 25:1043-1049.
40. Lesley, J., R. Hyman, and P. W. Kincade. 1993. CD44 and its interaction with extracellular matrix. Adv. Immunol. 54:271-335.
41. Reinhold, M. I., F. P. Lindberg, D. Plas, S. Reynolds, M. G. Peters, and E. J. Brown. 1995. In vivo expression of alternatively spliced forms of integrin-associated protein (CD47). J. Cell Sci. 108:3419-3425.